Two studies appear in this issue of JAMA Internal Medicine that will inform continuing efforts
to improve the effectiveness of cervical cancer screening. 3, 4 In the first study, Sawaya and
colleagues3 report a cost-effectiveness analysis of a variety of screening strategies, in which
the preferences of a diverse set of patients from 2 clinics are incorporated. They find that 2
strategies are the most cost-effective options. The first option is Papanicolaou testing every 3
years in women at average risk of cervical cancer (not immune suppressed and not …